drugset / Trial / NCT00879905

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

NCT00879905 ↗

Phase 1 Completed 64 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.

Timeline

Start
2009-05
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HSP990 Unknown — Oral